Biogen beats Q1 estimates
Drugmaker Biogen beat analysts' estimates for first-quarter on higher sales of its growth driver Spinraza.
Net income attributable to the company rose 20 percent to $1.41 billion, in the quarter ended March 31. On an adjusted basis, the company earned $6.98 per share on revenue of $3.49 billion. Analysts had expected the company to earn $6.87 per share on revenue of $3.39 billion.
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
The average market capitalization across the Pharmaceuticals: Major Industry is 81.2B. The market cap for tickers in the group ranges from 72.83K to 540.76B. LLY holds the highest valuation in this group at 540.76B. The lowest valued company is CRXTQ at 72.83K.
High and low price notable news
The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 1%. MIRA experienced the highest price growth at 26%, while SCLX experienced the biggest fall at -22%.
The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was 10%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 28
P/E Growth Rating: 59
Price Growth Rating: 55
SMR Rating: 57
Profit Risk Rating: 67
Seasonality Score: -18 (-100 ... +100)